1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research & Forecasting
2.1. Research Methodology
2.1.1. Research Process
2.1.2. Research Framework
2.1.3. Research Reliability & Validity
2.1.4. Research Assumptions
2.2. Forecasting Methodology
2.3. Research Outcome
2.3.1. 360iResearch Competitive Strategic Window
2.3.1.1. Leverage Zone
2.3.1.2. Vantage Zone
2.3.1.3. Speculative Zone
2.3.1.4. Bottleneck Zone
2.3.2. 360iResearch FPNV Positioning Matrix
2.3.2.1. 360iResearch Quadrants
2.3.2.1.1. Forefront
2.3.2.1.2. Pathfinders
2.3.2.1.3. Niche
2.3.2.1.4. Vital
2.3.2.2. Business Strategy
2.3.2.2.1. Business Growth
2.3.2.2.2. Industry Coverage
2.3.2.2.3. Financial Viability
2.3.2.2.4. Channel Support
2.3.2.3. Product Satisfaction
2.3.2.3.1. Value for Money
2.3.2.3.2. Ease of Use
2.3.2.3.3. Product Features
2.3.2.3.4. Customer Support
3. Executive Summary
3.1. Outlook in the Biomaterials Market
3.2. Opportunities in the Biomaterials Market
4. Premium Insight
4.1. Market Connectivity
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter's Five Forces Analysis
4.3.1. Threat of New Entrants
4.3.2. Threat of Substitutes
4.3.3. Bargaining Power of Customers
4.3.4. Bargaining Power of Suppliers
4.3.5. Industry Rivalry
4.4. Industry Trends
5. South Africa Biomaterials Market: Type Estimates & Trend Analysis
5.1. Overview
5.2. Market Sizing & Forecasting
6. South Africa Biomaterials Market: Classification Estimates & Trend Analysis
6.1. Overview
6.2. Market Sizing & Forecasting
7. South Africa Biomaterials Market: Application Estimates & Trend Analysis
7.1. Overview
7.2. Market Sizing & Forecasting
8. Competitive Landscape
8.1. 360iResearch FPNV Positioning Matrix for South Africa Biomaterials Market
8.2. Market Vendor Ranking Analysis for South Africa Biomaterials Market
8.3. Competitive News Feed Analysis for South Africa Biomaterials Market
8.3.1. Mergers & Acquisitions
8.3.2. New Product Launches
8.3.3. Business Expansions
8.3.4. Partnerships, Agreements & Collaborations
9. Company Usability Profiles
9.1. Berkeley Advanced Biomaterials, Inc.
9.1.1. Business Overview
9.1.2. FPNV Scorecard
9.1.3. Business SWOT
9.1.4. Business Strategy
9.2. Corbion N.V.
9.2.1. Business Overview
9.2.2. FPNV Scorecard
9.2.3. Business SWOT
9.2.4. Business Strategy
9.3. Geistlich Pharma AG
9.3.1. Business Overview
9.3.2. FPNV Scorecard
9.3.3. Business SWOT
9.3.4. Business Strategy
9.4. Ingredion Inc
9.4.1. Business Overview
9.4.2. FPNV Scorecard
9.4.3. Business SWOT
9.4.4. Business Strategy
9.5. Koninklijke DSM N.V.
9.5.1. Business Overview
9.5.2. FPNV Scorecard
9.5.3. Business SWOT
9.5.4. Business Strategy
9.6. Altis Biologics Pty Ltd
9.6.1. Business Overview
9.6.2. FPNV Scorecard
9.6.3. Business SWOT
9.6.4. Business Strategy
9.7. Biomet, Inc.
9.7.1. Business Overview
9.7.2. FPNV Scorecard
9.7.3. Business SWOT
9.7.4. Business Strategy
9.8. Borregaard ASA
9.8.1. Business Overview
9.8.2. FPNV Scorecard
9.8.3. Business SWOT
9.8.4. Business Strategy
9.9. Kruger Inc.
9.9.1. Business Overview
9.9.2. FPNV Scorecard
9.9.3. Business SWOT
9.9.4. Business Strategy
9.10. Sappi Group
9.10.1. Business Overview
9.10.2. FPNV Scorecard
9.10.3. Business SWOT
9.10.4. Business Strategy
10. Appendix
10.1. Discussion Guide
10.2. Top Reports
10.3. Author Details